image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - US
$ 7.72
-16.7 %
$ 418 M
Market Cap
-1.97
P/E
1. INTRINSIC VALUE

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate.[ Read More ]

The intrinsic value of one EBS stock under the base case scenario is HIDDEN Compared to the current market price of 7.72 USD, Emergent BioSolutions Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EBS

image
FINANCIALS
1.05 B REVENUE
-6.39%
-726 M OPERATING INCOME
-337.59%
-760 M NET INCOME
-239.81%
-206 M OPERATING CASH FLOW
-504.99%
212 M INVESTING CASH FLOW
155.68%
-536 M FINANCING CASH FLOW
-111.33%
270 M REVENUE
5.81%
64.5 M OPERATING INCOME
140.54%
115 M NET INCOME
140.55%
154 M OPERATING CASH FLOW
223.58%
112 M INVESTING CASH FLOW
2534.78%
-180 M FINANCING CASH FLOW
-254.22%
Balance Sheet Decomposition Emergent BioSolutions Inc.
image
Current Assets 680 M
Cash & Short-Term Investments 112 M
Receivables 191 M
Other Current Assets 377 M
Non-Current Assets 1.14 B
Long-Term Investments 0
PP&E 399 M
Other Non-Current Assets 745 M
Current Liabilities 651 M
Accounts Payable 112 M
Short-Term Debt 414 M
Other Current Liabilities 125 M
Non-Current Liabilities 523 M
Long-Term Debt 460 M
Other Non-Current Liabilities 62.3 M
EFFICIENCY
Earnings Waterfall Emergent BioSolutions Inc.
image
Revenue 1.05 B
Cost Of Revenue 705 M
Gross Profit 344 M
Operating Expenses 1.04 B
Operating Income -726 M
Other Expenses 34.1 M
Net Income -760 M
RATIOS
32.77% GROSS MARGIN
32.77%
-69.23% OPERATING MARGIN
-69.23%
-72.48% NET MARGIN
-72.48%
-117.13% ROE
-117.13%
-41.71% ROA
-41.71%
-50.05% ROIC
-50.05%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Emergent BioSolutions Inc.
image
Net Income -760 M
Depreciation & Amortization 125 M
Capital Expenditures -51.6 M
Stock-Based Compensation 23.1 M
Change in Working Capital -70.3 M
Others 425 M
Free Cash Flow -258 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Emergent BioSolutions Inc.
image
EBS has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Emergent BioSolutions Inc.
image
Sold
0-3 MONTHS
444 K USD 2
3-6 MONTHS
75.8 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
5 days ago
Nov 12, 2024
Sell 273 K USD
DeGolyer Donald W
Director
- 25000
10.91 USD
6 days ago
Nov 11, 2024
Sell 171 K USD
White Marvin L
Director
- 14287
11.97 USD
5 months ago
Jun 04, 2024
Sell 61.1 K USD
Zoon Kathryn C
Director
- 10000
6.11 USD
5 months ago
May 29, 2024
Sell 8.44 K USD
Zoon Kathryn C
Director
- 1830
4.61 USD
5 months ago
May 21, 2024
Sell 6.29 K USD
Zoon Kathryn C
Director
- 1089
5.78 USD
1 year ago
May 25, 2023
Sell 14.2 K USD
Zoon Kathryn C
Director
- 1700
8.38 USD
1 year ago
Jun 02, 2023
Sell 15.3 K USD
Zoon Kathryn C
Director
- 1830
8.35 USD
1 year ago
Nov 25, 2022
Sell 22.8 K USD
Richard Ronald
Director
- 1912
11.94 USD
2 years ago
Jun 09, 2022
Sell 37 K USD
Zoon Kathryn C
director:
- 1173
31.52 USD
2 years ago
May 24, 2022
Sell 70.9 K USD
Zoon Kathryn C
director:
- 1996
35.53 USD
3 years ago
Nov 15, 2021
Bought 112 K USD
LINDAHL RICHARD S
EVP, Chief Financial Officer
+ 3000
37.46 USD
3 years ago
May 25, 2021
Sell 177 K USD
Zoon Kathryn C
Director
- 3139
56.48 USD
3 years ago
Mar 04, 2021
Sell 754 K USD
Bailey Sue
Director
- 8168
92.37 USD
3 years ago
Mar 01, 2021
Sell 1.71 M USD
Havey Adam
EVP, Business Operations
- 17134
99.62 USD
3 years ago
Mar 01, 2021
Sell 1.99 M USD
Havey Adam
EVP, Business Operations
- 20145
99.02 USD
3 years ago
Feb 08, 2021
Sell 1.56 M USD
Kramer Robert
President and CEO
- 13000
120.03 USD
3 years ago
Jan 20, 2021
Sell 246 K USD
Kramer Robert
President and CEO
- 2232
110 USD
3 years ago
Jan 21, 2021
Sell 2.41 M USD
Kramer Robert
President and CEO
- 21900
110.03 USD
3 years ago
Jan 15, 2021
Sell 2.02 M USD
Kramer Robert
President and CEO
- 19026
106.0076 USD
4 years ago
Nov 09, 2020
Sell 1.91 M USD
El-Hibri Fuad
Chairman
- 20000
95.26 USD
4 years ago
Nov 10, 2020
Sell 1.71 M USD
El-Hibri Fuad
Chairman
- 19391
88.21 USD
4 years ago
Nov 02, 2020
Sell 1.81 M USD
El-Hibri Fuad
Chairman
- 20000
90.44 USD
4 years ago
Nov 03, 2020
Sell 1.81 M USD
El-Hibri Fuad
Chairman
- 20000
90.74 USD
4 years ago
Sep 23, 2020
Sell 1.31 M USD
El-Hibri Fuad
Chairman
- 13000
100.58 USD
4 years ago
Sep 24, 2020
Sell 1.24 M USD
El-Hibri Fuad
Chairman
- 12535
98.85 USD
4 years ago
Sep 16, 2020
Sell 2.05 M USD
El-Hibri Fuad
Chairman
- 20000
102.48 USD
4 years ago
Sep 17, 2020
Sell 2.01 M USD
El-Hibri Fuad
Chairman
- 20000
100.68 USD
4 years ago
Sep 09, 2020
Sell 2.06 M USD
El-Hibri Fuad
Chairman
- 20000
102.8 USD
4 years ago
Sep 10, 2020
Sell 2.05 M USD
El-Hibri Fuad
Chairman
- 20000
102.66 USD
4 years ago
Sep 02, 2020
Sell 878 K USD
SULLIVAN LOUIS W
Director
- 7893
111.2256 USD
4 years ago
Sep 02, 2020
Sell 2.28 M USD
SULLIVAN LOUIS W
Director
- 20525
111.2157 USD
4 years ago
Aug 18, 2020
Sell 599 K USD
Bailey Sue
Director
- 4665
128.3095 USD
4 years ago
Aug 17, 2020
Sell 884 K USD
Harsanyi Zsolt
Director
- 6609
133.7062 USD
4 years ago
Aug 11, 2020
Sell 745 K USD
JOULWAN GEORGE A
Director
- 6000
124.1059 USD
4 years ago
Aug 07, 2020
Sell 825 K USD
Richard Ronald
Director
- 6297
131 USD
4 years ago
Aug 10, 2020
Sell 130 K USD
Zoon Kathryn C
Director
- 1000
130.27 USD
4 years ago
Jun 03, 2020
Sell 575 K USD
Richard Ronald
Director
- 6572
87.514 USD
4 years ago
Jun 03, 2020
Sell 466 K USD
Bailey Sue
Director
- 5322
87.503 USD
4 years ago
May 26, 2020
Sell 373 K USD
Hauer Jerome M
Director
- 4385
85.1478 USD
4 years ago
May 26, 2020
Sell 348 K USD
Zoon Kathryn C
Director
- 4093
85.1019 USD
4 years ago
May 12, 2020
Sell 141 K USD
Zoon Kathryn C
Director
- 1660
85.2134 USD
4 years ago
May 11, 2020
Sell 405 K USD
Harsanyi Zsolt
Director
- 4940
81.9888 USD
4 years ago
May 11, 2020
Sell 170 K USD
JOULWAN GEORGE A
Director
- 2000
85.1856 USD
4 years ago
May 05, 2020
Sell 672 K USD
Richard Ronald
Director
- 8375
80.1945 USD
4 years ago
Apr 29, 2020
Sell 1.48 M USD
El-Hibri Fuad
Chairman
- 20000
74.24 USD
4 years ago
Apr 30, 2020
Sell 1.48 M USD
El-Hibri Fuad
Chairman
- 20000
74.01 USD
4 years ago
Apr 27, 2020
Sell 616 K USD
Richard Ronald
Director
- 7893
78 USD
4 years ago
Apr 22, 2020
Sell 1.34 M USD
El-Hibri Fuad
Chairman
- 20000
66.81 USD
4 years ago
Apr 23, 2020
Sell 1.37 M USD
El-Hibri Fuad
Chairman
- 20000
68.49 USD
4 years ago
Apr 17, 2020
Sell 540 K USD
Havey Adam
EVP, Business Operations
- 20414
26.45 USD
4 years ago
Apr 20, 2020
Sell 525 K USD
Havey Adam
EVP, Business Operations
- 17009
30.86 USD
4 years ago
Apr 20, 2020
Sell 1.17 M USD
Havey Adam
EVP, Business Operations
- 17009
69 USD
4 years ago
Apr 17, 2020
Sell 1.33 M USD
Havey Adam
EVP, Business Operations
- 20414
65 USD
4 years ago
Apr 16, 2020
Sell 1.25 M USD
El-Hibri Fuad
Chairman
- 20000
62.47 USD
4 years ago
Apr 13, 2020
Sell 1.06 M USD
El-Hibri Fuad
Chairman
- 17071
62.25 USD
4 years ago
Apr 14, 2020
Sell 394 K USD
El-Hibri Fuad
Chairman
- 6261
62.99 USD
4 years ago
Apr 15, 2020
Sell 785 K USD
El-Hibri Fuad
Chairman
- 12537
62.58 USD
4 years ago
Apr 08, 2020
Sell 790 K USD
El-Hibri Fuad
Chairman
- 13000
60.75 USD
4 years ago
Apr 08, 2020
Sell 1.49 M USD
El-Hibri Fuad
Chairman
- 24362
61.34 USD
4 years ago
Apr 09, 2020
Sell 1.47 M USD
El-Hibri Fuad
Chairman
- 23716
61.83 USD
4 years ago
Apr 06, 2020
Sell 1.71 M USD
El-Hibri Fuad
Chairman
- 28240
60.5 USD
4 years ago
Apr 07, 2020
Sell 871 K USD
El-Hibri Fuad
Chairman
- 14336
60.76 USD
4 years ago
Apr 06, 2020
Sell 255 K USD
Havey Adam
EVP, Business Operations
- 4242
60 USD
4 years ago
Apr 06, 2020
Sell 224 K USD
Havey Adam
EVP, Business Operations
- 3730
60 USD
4 years ago
Apr 06, 2020
Sell 96.7 K USD
Kirk Sean
EVP, Manufacturing & Tech Ops
- 3135
30.86 USD
4 years ago
Apr 06, 2020
Sell 223 K USD
Kirk Sean
EVP, Manufacturing & Tech Ops
- 7293
30.63 USD
4 years ago
Apr 06, 2020
Sell 438 K USD
Kirk Sean
EVP, Manufacturing & Tech Ops
- 7293
60 USD
4 years ago
Mar 16, 2020
Sell 416 K USD
Harsanyi Zsolt
Director
- 6400
65 USD
4 years ago
Mar 04, 2020
Sell 60.1 K USD
Zoon Kathryn C
Director
- 991
60.6493 USD
4 years ago
Mar 04, 2020
Sell 465 K USD
SULLIVAN LOUIS W
Director
- 7893
58.9582 USD
4 years ago
Feb 27, 2020
Sell 374 K USD
Bailey Sue
Director
- 6572
56.9282 USD
4 years ago
Feb 26, 2020
Sell 799 K USD
El-Hibri Fuad
Chairman
- 13619
58.7 USD
4 years ago
Feb 27, 2020
Sell 560 K USD
El-Hibri Fuad
Chairman
- 9837
56.97 USD
4 years ago
Feb 21, 2020
Sell 335 K USD
Richard Ronald
Director
- 5152
65 USD
4 years ago
Feb 21, 2020
Sell 460 K USD
Hauer Jerome M
Director
- 6572
70 USD
4 years ago
Feb 21, 2020
Sell 1.2 M USD
El-Hibri Fuad
Chairman
- 18567
64.9 USD
4 years ago
Feb 18, 2020
Sell 998 K USD
El-Hibri Fuad
Chairman
- 15614
63.9 USD
4 years ago
Feb 12, 2020
Sell 863 K USD
El-Hibri Fuad
Chairman
- 13720
62.9 USD
4 years ago
Feb 05, 2020
Sell 2.93 M USD
El-Hibri Fuad
Executive Chairman
- 48316
60.66 USD
4 years ago
Feb 06, 2020
Sell 723 K USD
El-Hibri Fuad
Executive Chairman
- 11684
61.9 USD
4 years ago
Jan 16, 2020
Sell 189 K USD
Harsanyi Zsolt
Director
- 3435
55 USD
4 years ago
Dec 12, 2019
Sell 448 K USD
Bailey Sue
Director
- 8375
53.46 USD
5 years ago
Nov 18, 2019
Sell 54.3 K USD
Zoon Kathryn C
Director
- 1000
54.314 USD
5 years ago
Nov 08, 2019
Sell 167 K USD
Zoon Kathryn C
Director
- 3082
54.1481 USD
5 years ago
Nov 07, 2019
Sell 309 K USD
Richard Ronald
Director
- 5153
60 USD
5 years ago
Sep 09, 2019
Sell 84.7 K USD
Zoon Kathryn C
Director
- 1509
56.1246 USD
5 years ago
May 28, 2019
Sell 59.7 K USD
Zoon Kathryn C
Director
- 1376
43.3884 USD
5 years ago
Mar 11, 2019
Sell 138 K USD
Havey Adam
EVP, Business Operations
- 2430
56.93 USD
5 years ago
Feb 28, 2019
Sell 59 K USD
Havey Adam
EVP, Business Operations
- 1019
57.9218 USD
5 years ago
Mar 01, 2019
Sell 118 K USD
Havey Adam
EVP, Business Operations
- 2024
58.2 USD
5 years ago
Mar 04, 2019
Sell 846 K USD
Abdun-Nabi Daniel
CEO
- 14565
58.107 USD
5 years ago
Feb 26, 2019
Sell 619 K USD
El-Hibri Fuad
Chairman
- 10369
59.65 USD
5 years ago
Feb 28, 2019
Sell 409 K USD
El-Hibri Fuad
Chairman
- 6987
58.47 USD
5 years ago
Feb 27, 2019
Sell 604 K USD
El-Hibri Fuad
Chairman
- 10369
58.24 USD
5 years ago
Nov 27, 2018
Sell 1.45 M USD
El-Hibri Fuad
Chairman
- 20832
69.59 USD
5 years ago
Nov 27, 2018
Sell 220 K USD
Bailey Sue
Director
- 3158
69.6197 USD
5 years ago
Nov 26, 2018
Sell 1.75 M USD
El-Hibri Fuad
Chairman
- 25000
69.96 USD
5 years ago
Nov 27, 2018
Sell 1.45 M USD
El-Hibri Fuad
Chairman
- 20832
69.59 USD
6 years ago
Nov 19, 2018
Sell 1.39 M USD
El-Hibri Fuad
Chairman
- 20000
69.54 USD
5 years ago
Nov 20, 2018
Sell 1.06 M USD
El-Hibri Fuad
Chairman
- 15173
70.03 USD
6 years ago
Nov 07, 2018
Sell 165 K USD
Zoon Kathryn C
Director
- 2371
69.4804 USD
6 years ago
Nov 07, 2018
Sell 131 K USD
Zoon Kathryn C
Director
- 1871
70.0789 USD
6 years ago
Nov 07, 2018
Sell 553 K USD
Richard Ronald
Director
- 7893
70 USD
6 years ago
Nov 06, 2018
Sell 278 K USD
JOULWAN GEORGE A
Director
- 4058
68.4535 USD
6 years ago
Nov 06, 2018
Sell 551 K USD
Harsanyi Zsolt
Director
- 8000
68.8992 USD
6 years ago
Nov 01, 2018
Sell 128 K USD
Havey Adam
EVP, Business Operations
- 2011
63.5 USD
6 years ago
Nov 02, 2018
Sell 398 K USD
Havey Adam
EVP, Business Operations
- 6168
64.5 USD
6 years ago
Oct 17, 2018
Sell 19.9 K USD
Havey Adam
EVP, Business Operations
- 314
63.5 USD
6 years ago
Oct 17, 2018
Sell 19.3 K USD
Havey Adam
EVP, Business Operations
- 314
61.5 USD
6 years ago
Oct 15, 2018
Sell 371 K USD
Havey Adam
EVP, Business Operations
- 6165
60.1549 USD
6 years ago
Oct 15, 2018
Sell 370 K USD
Havey Adam
EVP, Business Operations
- 6165
60.0293 USD
6 years ago
Oct 16, 2018
Sell 244 K USD
Havey Adam
EVP, Business Operations
- 3840
63.5 USD
6 years ago
Oct 15, 2018
Sell 40.1 K USD
Havey Adam
EVP, Business Operations
- 661
60.67 USD
6 years ago
Oct 16, 2018
Sell 379 K USD
Havey Adam
EVP, Business Operations
- 6165
61.5 USD
6 years ago
Sep 17, 2018
Sell 85.7 K USD
Abdun-Nabi Daniel
CEO
- 1319
65 USD
7. News
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats. seekingalpha.com - 1 week ago
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa. benzinga.com - 1 week ago
New Strong Buy Stocks for November 7th MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. zacks.com - 1 week ago
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript seekingalpha.com - 1 week ago
Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates Emergent Biosolutions (EBS) came out with quarterly earnings of $1.37 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to loss of $1.44 per share a year ago. zacks.com - 1 week ago
Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa GAITHERSBURG, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by PANTHER, under the leadership of the Africa Centres for Disease Control and Prevention (Africa CDC), as part of the ‘MpOx Study in Africa' (MOSA). The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial. globenewswire.com - 1 week ago
BlueOne Card Inc., Announces Definitive Agreement to Acquire Millennium EBS, Inc. in a $12 Million Deal BlueOne Card, Inc.(OTCQX: BCRD) a leading fintech provider of payment hub solutions and prepaid cards, announes an agreement to acquire Milennium EBS, Inc. globenewswire.com - 3 weeks ago
5 Broker Liked Stocks to Keep an Eye on After Recent Analyst Upgrades Investors should monitor stocks like AAL, ACDVF, EBS, BRY and CBRL for high returns. zacks.com - 3 weeks ago
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Emergent BioSolutions Inc. Common Stock - EBS GREENBELT, Md., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Maryland has approved the following announcement of a proposed class action settlement that would benefit purchasers of Emergent BioSolutions Inc. common stock (NYSE: EBS): globenewswire.com - 3 weeks ago
Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 GAITHERSBURG, Md., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, November 6, 2024, at 5:00 pm eastern time to discuss the financial results for the third quarter of 2024, recent business developments, and financial outlook for full year 2024. globenewswire.com - 3 weeks ago
Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emergent is working with businesses to prepare for accidental opioid emergencies by ensuring workplaces, facilities, and hospitality venues, among many other locations, should consider being equipped with NARCAN® Nasal Spray. In March 2024, Emergent joined the ‘White House Challenge to Save Lives from Overdose', a nationwide call encouraging leaders to commit to increasing education of and access to life-saving opioid overdose reversal medications. globenewswire.com - 1 month ago
Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario Emergent BioSolutions is showing signs of a potential turnaround with strategic restructuring, cost-cutting, and securing significant contracts in public health preparedness. Despite a challenging Q2, the company raised its full-year revenue forecast and is focusing on improving operational efficiency and reducing debt. Emergent's involvement in global health crises, like mpox, and securing FDA approvals and contracts, positions it as a key player in biodefense. seekingalpha.com - 1 month ago
8. Profile Summary

Emergent BioSolutions Inc. EBS

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 418 M
Dividend Yield 0.00%
Description Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Contact 400 Professional Drive, Gaithersburg, MD, 20879 https://www.emergentbiosolutions.com
IPO Date Nov. 15, 2006
Employees 1600
Officers Mr. Richard S. Lindahl M.B.A. Executive Vice President, Chief Financial Officer & Treasurer Ms. Coleen Glessner Executive Vice President of Global Quality and Ethics & Compliance Mr. Joseph C. Papa Jr. Chief Executive Officer, President & Director Mr. Paul A. Williams Senior Vice President of Products Business Ms. Michelle Pepin Senior Vice President & Chief Human Resource Officer Ms. Stephanie Duatschek Senior Vice President, Chief Strategy & Transformation Officer